Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Archive Search

5 results
12:00 AM, Feb 27, 2006  |  BioCentury | Product Development

Targeted =/ narrow

is DNA's psoriasis drug Raptiva efalizumab, a humanized MAb against CD11a, the alpha subunit of LFA-1
By binding to CD11a, LFA-1 is prevented from binding with its ligand, ICAM-1 . Interaction …
between LFA-1 and ICAM-1 contributes to the initiation and maintenance of multiple processes, including activation of …
12:00 AM, Mar 29, 2004  |  BioCentury | Product Development

PsA is not RA

to the CD11a receptor on T cells, downregulating the receptor and its larger family of LFA-1
12:00 AM, May 19, 2003  |  BioCentury | Product Development

Raptiva: Round up the usual suspects

to the CD11a receptor on T cells, downregulating the receptor and its larger family of LFA-1
12:00 AM, Jul 15, 2002  |  BioCentury | Product Development

Multiple drugs, multiple targets

cell function. The recombinant humanized anti-CD11a antibody binds to and blocks the functional activity of LFA-1
12:00 AM, Jul 15, 2002  |  BioCentury | Product Development

Treatment options

review Biogen Once weekly/IV or IM CD2 Xanelim Phase III Genentech, Xoma Once weekly/SC CD11a (LFA-1